Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults

M. Petráš, V. Oleár, M. Molitorisová, J. Dáňová, AM. Čelko, E. Nováková, M. Štefkovičová, Z. Krištúfková, J. Malinová, IK. Lesná,

. 2019 ; 7 (4) : . [pub] 20191007

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044236

We assessed the long-term persistence of humoral immunity against diphtheria in adults with childhood vaccination and the immunogenicity of a booster dose considering demographic, behavioural and vaccinating factors. We conducted a trial in 200 healthy Slovak adults aged 24-65 years, immunised against diphtheria in childhood and against tetanus at regular 10-15 year intervals, and receiving a dose of a tetanus-diphtheria toxoid vaccine. The response was determined by ELISA antibody concentrations of paired sera before and at 4 weeks post-vaccination. A seroprotection rate of 21% (95% confidence interval, CI 15.6-27.3%) was found in adults up to 59 years since the last vaccination with seroprotective levels of antibodies against diphtheria ≥0.1 IU/mL and a geometric mean concentration of 0.05 IU/mL. Conversely, seropositive levels ≥0.01 IU/mL were observed in 98% of adults (95% CI 95-99.5%). Booster-induced seroprotection was achieved in 78% of adults (95% CI 71.6-83.5%) clearly depending on pre-booster antibody levels correlating with age and time since the last vaccination. Moreover, only 54.2% of smokers and 53.3% of patients on statins exhibited seroprotection. Booster vaccination against diphtheria was unable to confer seroprotection in all recipients of only childhood vaccination.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044236
003      
CZ-PrNML
005      
20250611114023.0
007      
ta
008      
200107s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/vaccines7040139 $2 doi
035    __
$a (PubMed)31591336
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Petráš, Marek $u Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic. marek.petras@lf3.cuni.cz.
245    10
$a Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults / $c M. Petráš, V. Oleár, M. Molitorisová, J. Dáňová, AM. Čelko, E. Nováková, M. Štefkovičová, Z. Krištúfková, J. Malinová, IK. Lesná,
520    9_
$a We assessed the long-term persistence of humoral immunity against diphtheria in adults with childhood vaccination and the immunogenicity of a booster dose considering demographic, behavioural and vaccinating factors. We conducted a trial in 200 healthy Slovak adults aged 24-65 years, immunised against diphtheria in childhood and against tetanus at regular 10-15 year intervals, and receiving a dose of a tetanus-diphtheria toxoid vaccine. The response was determined by ELISA antibody concentrations of paired sera before and at 4 weeks post-vaccination. A seroprotection rate of 21% (95% confidence interval, CI 15.6-27.3%) was found in adults up to 59 years since the last vaccination with seroprotective levels of antibodies against diphtheria ≥0.1 IU/mL and a geometric mean concentration of 0.05 IU/mL. Conversely, seropositive levels ≥0.01 IU/mL were observed in 98% of adults (95% CI 95-99.5%). Booster-induced seroprotection was achieved in 78% of adults (95% CI 71.6-83.5%) clearly depending on pre-booster antibody levels correlating with age and time since the last vaccination. Moreover, only 54.2% of smokers and 53.3% of patients on statins exhibited seroprotection. Booster vaccination against diphtheria was unable to confer seroprotection in all recipients of only childhood vaccination.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Oleár, Vladimir $u Faculty of Healthcare, Alexander Dubček University of Trenčín, 911 50 Trenčín, Slovakia. vladimirolear@gmail.com.
700    1_
$a Molitorisová, Milica $u Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia. jana.danova@lf3.cuni.cz.
700    1_
$a Dáňová, Jana $u Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic. martin.celko@lf3.cuni.cz.
700    1_
$a Čelko, Alexander M $u Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic. jana.malinova@fnkv.cz.
700    1_
$a Nováková, Elena $u Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia. tn.stefkovicova@uvzsr.sk.
700    1_
$a Štefkovičová, Mária $u Faculty of Healthcare, Alexander Dubček University of Trenčín, 911 50 Trenčín, Slovakia. milica.molitorisova@uniba.sk.
700    1_
$a Krištúfková, Zuzana $u Faculty of Public Health, Slovak Medical University in Bratislava, 831 01 Bratislava, Slovakia. elena.novakova@uniba.sk.
700    1_
$a Malinová, Jana $u Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic. kristufkova@gmail.com.
700    1_
$a Lesná, Ivana K. $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21Prague, Czech Republic. $7 xx0112415
773    0_
$w MED00200686 $t Vaccines $x 2076-393X $g Roč. 7, č. 4 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31591336 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20250611114015 $b ABA008
999    __
$a ind $b bmc $g 1480825 $s 1082906
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 4 $e 20191007 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
LZP    __
$a Pubmed-20200107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace